Xinghuan Wang to Antibodies, Viral
This is a "connection" page, showing publications Xinghuan Wang has written about Antibodies, Viral.
Connection Strength
0.331
-
Seroprevalence of SARS-CoV-2 immunoglobulin antibodies in Wuhan, China: part of the city-wide massive testing campaign. Clin Microbiol Infect. 2021 Feb; 27(2):253-257.
Score: 0.086
-
Low prevalence of IgG antibodies to SARS-CoV-2 in cancer patients with COVID-19. Int J Cancer. 2020 12 01; 147(11):3267-3269.
Score: 0.084
-
Recurrent positive SARS-CoV-2: Immune certificate may not be valid. J Med Virol. 2020 11; 92(11):2384-2386.
Score: 0.084
-
SARS-CoV-2-specific immune response in COVID-19 convalescent individuals. Signal Transduct Target Ther. 2021 07 07; 6(1):256.
Score: 0.023
-
Impact of Treatment Regimens on Antibody Response to the SARS-CoV-2 Coronavirus. Front Immunol. 2021; 12:580147.
Score: 0.022
-
Factors affecting antibody response to SARS-CoV-2 in patients with severe COVID-19. J Med Virol. 2021 02; 93(2):612-614.
Score: 0.021
-
Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial. Lancet Infect Dis. 2021 12; 21(12):1654-1664.
Score: 0.006
-
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020 08 15; 396(10249):479-488.
Score: 0.005